Catherine Ludolph
About Catherine Ludolph
Catherine Ludolph is a Specialist and Research Associate in Gene Editing Process & Analytical Development at Bristol Myers Squibb in Seattle, Washington, with a background in bioengineering and chemical engineering.
Company
Catherine Ludolph is currently working at Bristol Myers Squibb in Seattle, Washington, United States. She holds the position of Specialist, Research Associate in the Gene Editing Process and Analytical Development team.
Title
Catherine Ludolph serves as a Specialist, Research Associate in Gene Editing Process and Analytical Development at Bristol Myers Squibb. Her role involves advancing upstream process development of viral vectors for CAR T cell therapy products.
Education and Expertise
Catherine Ludolph graduated with a Bachelor of Science in Chemical Engineering from The University of Texas at Austin, where she studied from 2016 to 2020. She also holds a Master’s degree in Bioengineering from Rice University, completed in one year (2020-2021). Additionally, she studied Chemical Engineering at Universitat Pompeu Fabra for 11 months. Her expertise spans polymer science, cell culture, MATLAB, Microsoft Excel, Python, SolidWorks, and biodesign.
Background
Catherine Ludolph's professional background includes a variety of research positions. She worked as a Vaccine Process Research & Development Intern (Downstream) at Merck, where she validated the re-use of chromatography resin in live virus vaccine processing. Prior to this, she was a Research Intern at Vanderbilt Institute of Nanoscale Science and Engineering (VINSE) in Greater Nashville Area, TN, and an Undergraduate Researcher at Cockrell School of Engineering, The University of Texas at Austin. During her academic tenure, her research focused on polymer synthesis for biosensing and drug delivery.
Achievements
Catherine Ludolph has made significant contributions to various projects. As part of a graduate design project at Rice University, she developed a low-cost cervical cancer training device in collaboration with Rice360. Her research experience includes conducting experiments on the culture and expansion of mammalian cells, transfection of cells with viral DNA, and the harvest of viral vector products. At Bristol Myers Squibb, she supports the development of CAR T cell therapy products by optimizing the upstream process of viral vectors.